Oxyphenonium
| Evidence Level: L4 | Predicted Indications: 1 |
Table of Contents
Oxyphenonium: From Gastric and Duodenal Ulcer to Irritable Bowel Syndrome
One-Sentence Summary
Oxyphenonium is a quaternary ammonium anticholinergic (antimuscarinic) agent historically used for gastric and duodenal ulcer. The TxGNN model predicts it may be effective for Irritable Bowel Syndrome (IBS), but this direction is currently supported by only 1 publication and no registered clinical trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not licensed in India; historically used for gastric and duodenal ulcer (source: pharmacology database) |
| Predicted New Indication | Irritable Bowel Syndrome |
| TxGNN Prediction Score | 99.08% |
| Evidence Level | L4 |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed, TFDA/CDSCO-sourced mechanism-of-action documentation is not currently available for Oxyphenonium (flagged as a High-severity data gap). Based on pharmacology database records available in this evidence pack, Oxyphenonium is a synthetic quaternary ammonium compound that acts on muscarinic receptors (target: CHRM4 / M4 receptor, human), consistent with its classification as an antimuscarinic antispasmodic historically used to treat gastric and duodenal ulcer.
Mechanistically, Oxyphenonium’s antimuscarinic activity inhibits smooth-muscle muscarinic receptors (M3-type) in the gastrointestinal tract, reducing gut motility and spasm. This mode of action is the same pharmacological principle used by other antispasmodics (e.g., dicyclomine, hyoscine) that are already applied to relieve IBS symptoms, particularly diarrhea-predominant/spasm-type presentations.
The TxGNN model’s high score (0.99) reflects strong structural similarity between this drug class and the IBS indication within the knowledge graph, rather than direct clinical evidence for Oxyphenonium itself. The mechanistic rationale is plausible, but independent confirmatory data (trials, MOA documentation, safety labeling) are still needed before this signal can be considered clinically actionable.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 24933967 | 2013 | Other/Unclear (non-RCT, abstract-level evidence) | Eksperimental’naia i klinicheskaia gastroenterologiia | Reports on use of methocinium iodide (a related quaternary ammonium antimuscarinic) in patients with irritable bowel syndrome; abstract-level, non-randomized evidence |
India Market Information
Currently not marketed in India; no registration records available.
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA/CDSCO label warnings and contraindications are marked as a Blocking data gap and could not be retrieved for this evaluation, which prevents a full S1 safety assessment.)
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic rationale for IBS is biologically plausible given Oxyphenonium’s antimuscarinic activity, but the current evidence base is limited to a single non-randomized, abstract-level publication with no registered clinical trials — corresponding to evidence level L4. The drug is also not currently marketed in India, and safety labeling data is unavailable.
To proceed, the following is needed:
- Official TFDA/CDSCO label (warnings and contraindications) to complete the S1 safety assessment (currently a Blocking gap)
- Confirmed detailed mechanism-of-action documentation (currently a High-severity gap)
- Additional clinical evidence (trials or higher-tier studies) specific to Oxyphenonium in IBS, beyond the single 2013 abstract-level report
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.